We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Gilead Sciences Stock Climb After Q3 Earnings?
Read MoreHide Full Article
Big Pharma will close out this week’s earnings reports, with Gilead Sciences (GILD - Free Report) set to give its Q3 results on October 27. The biopharmaceutical giant has held up well this year compared to the broader market with GILD only 5% from its highs.
With Gilead Sciences edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.
Image Source: Zacks Investment Research
GILD Overview
Gilead Sciences’ revenue is derived from its treatments in human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases. GILD’s portfolio also includes drugs for Hepatitis C.
Last quarter, revenue increased 1% from Q2 2021 to $6.3 billion. This was highlighted by a 71% year over year increase in oncology sales at $527 million. The company also saw strong demand in its HIV portfolio with its Biktarvy sales up 28% year over year to $2.6 billion.
Investors will hope that Gilead Sciences HIV expansion can continue to grow along with its oncology and liver disease treatments. While current inflationary environments could scale back volume, consumers will usually spare no expense on essential medicines even during a market downturn.
Q3 Outlook
The Zacks Consensus Estimate for GILD’s Q3 earnings is $1.44 per share, which would represent a decline of - 45% from Q3 2021. Sales for Q3 are expected to be down -17% at $6.12 billion. Estimates for the period have gone down from $1.54 per share at the beginning of the quarter.
Year over year, GILD earnings are expected to decline -10% in 2022 and virtually be flat in FY23 at $6.51 per share. Top line growth is expected to decline, with sales down -7% this year and another -3% in FY23 to $24.52 billion.
However, GILD shares have rallied nicely going into the quarterly release as Q4 and FY23 earnings estimate revisions are starting to rise.
Performance & Valuation
Year to date GILD is only down -3% to outperform the S&P 500’s -20%. This has also outperformed its peer group’s -41% and the Medical-Biomedical/Genetic Market’s -24%. Even better, GILD’s total return is +1% YTD when adding in its strong dividend.
Image Source: Zacks Investment Research
Gilead Sciences has been a pioneer and industry leader. Over the last decade GILD’s total return is +171%. While this underperformed the benchmark, it has blasted its peer group’s +93% and its Zacks Subindustry’s +37%.
Trading around $70 per share, GILD has a P/E of 10.6X. This is lower than the industry average of 20.1X, which includes some noteworthy companies such as Amgen (AMGN - Free Report) and Moderna (MRNA - Free Report) . Plus, GILD still trades at a discount to its decade-high of 38.4X and is close to the median of 9.8X.
Image Source: Zacks Investment Research
Bottom Line
Going into Q3 earnings GILD lands a Zacks Rank #3 (Hold) and its Medical-Biomedical and Genetics Industry is in the top 23% of over 250 Zacks Industries. GILD also offers longer-term investors a solid 4.20% annual dividend yield at $2.92 per share. And the Average Zacks Price Target still suggests 4% upside from current levels.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Gilead Sciences Stock Climb After Q3 Earnings?
Big Pharma will close out this week’s earnings reports, with Gilead Sciences (GILD - Free Report) set to give its Q3 results on October 27. The biopharmaceutical giant has held up well this year compared to the broader market with GILD only 5% from its highs.
With Gilead Sciences edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.
Image Source: Zacks Investment Research
GILD Overview
Gilead Sciences’ revenue is derived from its treatments in human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases. GILD’s portfolio also includes drugs for Hepatitis C.
Last quarter, revenue increased 1% from Q2 2021 to $6.3 billion. This was highlighted by a 71% year over year increase in oncology sales at $527 million. The company also saw strong demand in its HIV portfolio with its Biktarvy sales up 28% year over year to $2.6 billion.
Investors will hope that Gilead Sciences HIV expansion can continue to grow along with its oncology and liver disease treatments. While current inflationary environments could scale back volume, consumers will usually spare no expense on essential medicines even during a market downturn.
Q3 Outlook
The Zacks Consensus Estimate for GILD’s Q3 earnings is $1.44 per share, which would represent a decline of - 45% from Q3 2021. Sales for Q3 are expected to be down -17% at $6.12 billion. Estimates for the period have gone down from $1.54 per share at the beginning of the quarter.
Year over year, GILD earnings are expected to decline -10% in 2022 and virtually be flat in FY23 at $6.51 per share. Top line growth is expected to decline, with sales down -7% this year and another -3% in FY23 to $24.52 billion.
However, GILD shares have rallied nicely going into the quarterly release as Q4 and FY23 earnings estimate revisions are starting to rise.
Performance & Valuation
Year to date GILD is only down -3% to outperform the S&P 500’s -20%. This has also outperformed its peer group’s -41% and the Medical-Biomedical/Genetic Market’s -24%. Even better, GILD’s total return is +1% YTD when adding in its strong dividend.
Image Source: Zacks Investment Research
Gilead Sciences has been a pioneer and industry leader. Over the last decade GILD’s total return is +171%. While this underperformed the benchmark, it has blasted its peer group’s +93% and its Zacks Subindustry’s +37%.
Trading around $70 per share, GILD has a P/E of 10.6X. This is lower than the industry average of 20.1X, which includes some noteworthy companies such as Amgen (AMGN - Free Report) and Moderna (MRNA - Free Report) . Plus, GILD still trades at a discount to its decade-high of 38.4X and is close to the median of 9.8X.
Image Source: Zacks Investment Research
Bottom Line
Going into Q3 earnings GILD lands a Zacks Rank #3 (Hold) and its Medical-Biomedical and Genetics Industry is in the top 23% of over 250 Zacks Industries. GILD also offers longer-term investors a solid 4.20% annual dividend yield at $2.92 per share. And the Average Zacks Price Target still suggests 4% upside from current levels.